|Taurolidine (Code C2639)|
|Terms & Properties|
Preferred Name: Taurolidine
Definition: A synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.
NCI-GLOSS Definition: A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called anti-infectives.
NCI Metathesaurus Link: C0144567 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||19388-87-5 (see NLM ChemIDplus info)|
|FDA UNII Code||8OBZ1M4V3V|
|PDQ Closed Trial Search ID||38354|
|PDQ Open Trial Search ID||38354 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
|Accepted_Therapeutic_Use_For||Bronchiectasis; Catheter-Related Sepsis; Otitis Media; Peritonitis; Thoracic Empyema|
Additional Concept Data:
|Defined Fully by Roles: No|